Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by Rock Springs Capital Management LP

Rock Springs Capital Management LP lifted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 3.9% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 74,000 shares of the biopharmaceutical company’s stock after purchasing an additional 2,750 shares during the quarter. Alnylam Pharmaceuticals comprises about 1.4% of Rock Springs Capital Management LP’s holdings, making the stock its 21st biggest holding. Rock Springs Capital Management LP owned about 0.06% of Alnylam Pharmaceuticals worth $24,484,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. Quantinno Capital Management LP lifted its holdings in Alnylam Pharmaceuticals by 32.3% during the 1st quarter. Quantinno Capital Management LP now owns 33,850 shares of the biopharmaceutical company’s stock worth $11,200,000 after buying an additional 8,258 shares in the last quarter. SummitTX Capital L.P. increased its position in shares of Alnylam Pharmaceuticals by 4.2% during the first quarter. SummitTX Capital L.P. now owns 3,611 shares of the biopharmaceutical company’s stock worth $1,195,000 after acquiring an additional 146 shares during the period. Lazard Asset Management LLC raised its stake in shares of Alnylam Pharmaceuticals by 60.4% in the first quarter. Lazard Asset Management LLC now owns 16,280 shares of the biopharmaceutical company’s stock valued at $5,387,000 after acquiring an additional 6,128 shares in the last quarter. Quadcap Wealth Management LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the first quarter valued at $234,000. Finally, Bradley Foster & Sargent Inc. CT boosted its holdings in Alnylam Pharmaceuticals by 71.6% in the first quarter. Bradley Foster & Sargent Inc. CT now owns 1,203 shares of the biopharmaceutical company’s stock valued at $398,000 after purchasing an additional 502 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $278.40 on Tuesday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 3.06 and a current ratio of 3.13. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $262.21 and a fifty-two week high of $495.55. The firm has a market capitalization of $37.17 billion, a PE ratio of 76.07 and a beta of 0.27. The stock’s 50-day simple moving average is $292.06 and its 200-day simple moving average is $315.16.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.87 by $1.12. The firm had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1.12 billion. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The firm’s quarterly revenue was up 96.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.44) earnings per share. As a group, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post 7.35 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. JPMorgan Chase & Co. cut their price target on Alnylam Pharmaceuticals from $420.00 to $400.00 and set an “overweight” rating on the stock in a report on Wednesday, July 22nd. Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Truist Financial cut their target price on shares of Alnylam Pharmaceuticals from $505.00 to $410.00 and set a “buy” rating on the stock in a research note on Monday, July 13th. Bank of America reduced their target price on shares of Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating on the stock in a report on Tuesday, July 14th. Finally, Citigroup initiated coverage on shares of Alnylam Pharmaceuticals in a research note on Tuesday, May 19th. They issued a “buy” rating and a $380.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $452.13.

Insiders Place Their Bets

In related news, Director David E. I. Pyott sold 3,830 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the transaction, the director directly owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. The trade was a 70.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is owned by insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.